91% of enterprise leaders now say data security, privacy, and risk will define their AI strategy over the next six months—and 77% call privacy a direct barrier to deployment, up from 53% a quarter ago. Privacy isn't a compliance checkbox anymore; it's a first-order investment category with real pricing power, and the privacy-by-design layer is separating into its own stack. Are you backing the gatekeepers, or still treating this as a feature play?

Asian VC hit $27.4B in Q1 — the highest quarterly total in over three years, with China accounting for $16.5B and claiming its third straight quarter of growth. The largest rounds went to AI-focused companies: StepFun's foundation model, Moonshot's agentic platform, and Galaxy Bot's robotics stack. The US owns the megarounds, China owns the agents — so where does your geographic thesis stand in a bipolar AI world?

OpenAI closed 6 acquisitions in Q1 2026 alone — nearly matching its entire 2025 total — capped by the Astral dev-tools deal on March 19. Frontier labs are no longer just training models; they're systematically acquiring the application layer, collapsing the traditional exit landscape for AI startups. If your moat isn't acquirer-proof, your only buyers are the same labs that might obsolete you — or no one at all.

80% of enterprises now cite cybersecurity as the #1 barrier to AI strategy—up from 68% a year ago—and Q1 2026 cyber funding proved the point: Cloaked $375M, Tenex.AI $250M, Upwind Security $250M. When the barrier becomes the bottleneck, the companies solving it earn pricing power and multi-hundred-million rounds. Are you positioned in the cyber-AI overlap, or watching capital flow to the firms that are?

Texas closed 106 deals at $6.24B in Q1, holding the #3 state position behind New York and California—Dallas led with 36, Austin 26, Houston 16. The Texas tech narrative isn't riding AI megarounds or chasing San Francisco's playbook; it's building a dependable third lane that doesn't need hype cycles to post volume. If your portfolio thesis bakes in concentration risk or narrative momentum, is "dependable and durable" the position you're underweighting?

Horizontal SaaS is down 35% over the past 12 months while vertical SaaS holds essentially flat at +3%, per Redpoint's 2026 Market Update — the application layer is rotating away from generic productivity and toward industry-specific AI-native tools. The megarounds are still chasing scale, but the sharpest Series A and B capital is now chasing depth in one industry. Which deck are you holding?

Enterprise AI budgets just hit an average of 207 million dollars per company while 42 percent have already ditched at least one AI project and 79 percent are actively struggling to make it work. The market isn't retreating though - it's splitting hard between a tiny group of companies that can clear the new security and governance gates and everyone else bleeding budget on pilots that never scale. Wildest shift: 63 percent of buyers now require human validation of AI outputs, up from just 22 percent a year ago, which means the fully autonomous agent pitch that dominated early 2025 is now basically a dealbreaker.

KKR just filed 14.7 billion dollars across two vehicles in Q1 and then dropped over 10 billion to build Helix — a platform designed to own the actual physical infrastructure of AI before most VCs even realized the game changed. While traditional venture was still writing Series B checks into software companies, private equity locked down data centers, power grids, and is now negotiating with Google to become the direct distribution layer for AI models into their portfolio companies. This isn't PE competing with VC anymore — it's PE rewriting what the capital stack even looks like, and if your fund strategy was built for a world where 500 million was considered large, you're not just outgunned, you're playing a sport that got reclassified.

While everyone obsessed over OpenAI's $122 billion raise, $4.3 billion quietly flowed through SEC filings into eight companies nobody talked about—inference chips, data infrastructure, AI hiring platforms—the actual plumbing that makes frontier AI work. Marvell raised $2 billion for custom silicon, MatX got $530 million for inference optimization, and Mercor landed $330 million targeting the skills gap that's killing 95% of enterprise AI pilots. The mega-rounds got the headlines but the SEC Form D tape just showed you what smart money is actually buying: the companies OpenAI can't operate without.

Pharma deal flow didn't collapse 62.5 percent last quarter — it just stopped filing as pharma. AI-native drug discovery companies like Recursion and Insitro are filing under "Other Technology" because their value lives in computational platforms, not clinical pipelines, which means healthcare funds tracking SEC codes are literally missing deals before they hit the committee. Total healthcare-adjacent deal count stayed completely flat at 74 deals, but if your allocation strategy runs on sector labels instead of manual tagging, you're benchmarking against a category that no longer describes where the actual capital is flowing.